The State Health Department Secretary publicly announced on Thursday that patients diagnosed with anxiety disorders and/or Tourette’s syndrome will be eligible to receive recommendations to legally access medical cannabis products. The new rules take effect on July 20.
Inhaled cannabis is effective and well-tolerated in patients with Tourette’s Syndrome, according to clinical data published online ahead of print in the Journal of Neuropsychiatry and Clinical Neuroscience. They concluded: “Overall, these study participants experienced substantial improvements in their symptoms. This is particularly striking given that almost all participants had failed at least one anti-tic medication trial.